These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
497 related articles for article (PubMed ID: 12530087)
1. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes. Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087 [TBL] [Abstract][Full Text] [Related]
2. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600 [TBL] [Abstract][Full Text] [Related]
3. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028 [TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176 [TBL] [Abstract][Full Text] [Related]
5. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420 [TBL] [Abstract][Full Text] [Related]
8. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma. Takahashi T; Irie RF; Nishinaka Y; Hoon DS Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820 [TBL] [Abstract][Full Text] [Related]
9. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
11. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related]
12. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913 [TBL] [Abstract][Full Text] [Related]
13. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247 [TBL] [Abstract][Full Text] [Related]
14. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058 [TBL] [Abstract][Full Text] [Related]
15. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody]. Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545 [TBL] [Abstract][Full Text] [Related]
16. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Dupont J; Latouche JB; Ma C; Sadelain M Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591 [TBL] [Abstract][Full Text] [Related]
17. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698 [TBL] [Abstract][Full Text] [Related]
18. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Zaks TZ; Rosenberg SA Cancer Res; 1998 Nov; 58(21):4902-8. PubMed ID: 9809997 [TBL] [Abstract][Full Text] [Related]
19. Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Lu J; Celis E Cancer Res; 2000 Sep; 60(18):5223-7. PubMed ID: 11016651 [TBL] [Abstract][Full Text] [Related]